The Russian Health Ministry has approved Avifavir for COVID-19, as reported Sputnik.
The drug was developed by the Russian Direct Investment Fund (RDIF) and ChemRar.
Avifavir is "the first antiviral drug registered against coronavirus in Russia," said CEO of the RDIF Kirill Dmitriev.
"It was developed and tested in clinical trials in Russia in an unprecedentedly short period of time enabling Avifavir to become the first registered drug based on Favipiravir in the world," Dmitriev added.
The final stage of Avifavir clinical trials involving 330 patients, recently approved by the national Health Ministry, is ongoing.
To read more NewsPoints articles, click here.